Lantern Pharma Inc.

Lantern Pharma Inc. (LTRN) shows no cyber incidents or red-flag 8-K filings in our 90-day monitoring window, but low signal over a short period does not indicate low overall risk; material events may exist outside this window. The full $49 Report extends analysis to 12 months of SEC filings, adds dilution risk scoring based on share issuance history, and flags AI-related operational risks relevant to the biotech sector. We also contextualize any financing activity, officer changes, and 8-K patterns that shape investor exposure. The full $49 Report adds quantified dilution risk, 12-month event timeline, and sector-specific risk signals that a 90-day snapshot cannot capture.